http://www.thenation.com/doc/20050530/mcgarvey"For Hager, those moral and ethical issues all appear to revolve around sex: In both his medical practice and his advisory role at the FDA, his ardent evangelical piety anchors his staunch opposition to emergency contraception, abortion and premarital sex. Through his six books--which include such titles as Stress and the Woman's Body and As Jesus Cared for Women, self-help tomes that interweave syrupy Christian spirituality with paternalistic advice on women's health and relationships--he has established himself as a leading conservative Christian voice on women's health and sexuality."
From DHS, Julie Myers
http://www.time.com/time/press_releases/article/0,8599,1109304,00.html"At the Department of Homeland Security, Julie Myers, 36, a well-connected but scantily credentialed White House aide, has been nominated to head the Immigration and Customs Enforcement agency, with 20,000 government employees and a $4 billion budget. The ICE is on the front lines of the war against terrorism, as well as drug smuggling, human trafficking and illegal arms running.
TIME reports "her nomination is a symptom of deeper ills in a huge new bureaucracy that the Bush Administration resisted creating. Among those problems, they say, is a tendency on the part of the Administration’s political appointees to discard in-house expertise, particularly when it could lead to additional government regulation of industry."
At The FDA, Scott Gottlieb (fomrer stockbroker which should tell you everything)
"At the Food and Drug Administration, TIME has learned, a 33-year-old doctor-turned-stock-analyst has second-guessed the drug-safety decisions of career scientists. TIME has obtained two internal e-mails showing how Scott Gottlieb, appointed in July to the FDA’s second-ranked post, deputy commissioner for medical and scientific affairs, has in recent weeks questioned two decisions.
One was not to approve a Oporia, a drug for osteoporosis, that could cost Pfizer $1 billion in annual revenue. Gottlieb also suggested it was "an overreaction" for the agency to halt the trial of a new multiple sclerosis drug, after three people developed a serious complications during the study, and one of them died. Gottlieb insists he would never interfere with drug approval decisions. “I would not be in a situation where I would be adjudicating the scientific or medical expertise of the (FDA) on a review matter,” he told TIME. “That’s not my role. It’s not my expertise. We defer to the career staff to make scientific and medical decisions.”